I disagree.
In order to be prepared for future audited
I disagree.
In order to be prepared for future audited financials, anything they put on paper now has to be just a correct.
I am guessing it's more a matter of paying for audits to be done more than anything else.
There are more pressing financial matters to deal with. I'm fine with un-audited financials until they are ready to make an major move to another market.
Revenue means everything. You cant pay for things if you don't have money and are self-sustaining audited financials or not. The bills are real and you need real money to pay for them.
If the eventually do a share buy back there should not be a need for an RS
Nanotech Entertainment Inc. (NTEK) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Top 5 Most Recently Viewed Articles
Understanding Oscar Health's Recent Options Activity In the fast-paced world of trading, Oscar Health Inc’s (NYSE: OSCR) recent options activity has captured significant attention among savvy investors. Notably, there has been a notable bullish sentiment from wealthy investors towards this health insurance company. Tracking public options data reveals movements that...
Continue Reading
Better Choice Company Settles on Halo Asia Sale Better Choice Company, Inc. (BTTR), a leader in pet health and wellness, has recently reached a significant milestone by signing a definitive agreement to sell its Halo business in Asia. This sale is projected to generate total gross proceeds of $8.1 million, which encompasses $6.5 million in cash at the closing of the deal....
Continue Reading
Fastenal Prepares for Earnings Report Fastenal (NASDAQ: FAST) is gearing up to release its quarterly earnings report. Investors are keenly anticipating the upcoming announcement, as it offers a glimpse into the company's financial performance. This article provides essential insights and analysis for those eager to understand what to expect from Fastenal's announcement....
Continue Reading
Compass Therapeutics Advances Cancer Research BOSTON — Compass Therapeutics, Inc. (Nasdaq: CMPX), a promising player in the biotechnology sphere focused on developing innovative therapies for cancer, has made significant strides in its clinical research. The company has announced that the first patient has been dosed in a groundbreaking Investigator Sponsored Trial...
Continue Reading
Overview of the ECB Fine Imposed on LHV Group The European Central Bank (ECB) has recently informed AS LHV Group about a decision to levy an administrative fine amounting to EUR 405 thousand. This fine is linked to an error identified in the consolidated regulatory reporting for a specified timeframe. The issue arose from discrepancies in how the equity of LHV Bank...
Continue Reading
